← All trials
NCT05985954
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Mar 28, 2026
- Completion date
- Mar 28, 2028
- First posted
- Aug 14, 2023
- Last posted
- Oct 16, 2023
- Enrollment
- 27
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- Eli LillyCollaborator
- BioMed Valley Discoveries, IncCollaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.